New Drug with Methotrexate for Active Rheumatoid Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests if a new drug (Natrunix) combined with methotrexate can better control active rheumatoid arthritis in people whose RA is still active despite methotrexate alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate to severe rheumatoid arthritis (RA) that is not well controlled with methotrexate alone.
- You must be taking methotrexate (10–25 mg per week) for at least 3 months, and be willing to keep taking it during the study.
- You must have at least 6 tender and 6 swollen joints, and your DAS-ESR score must be above 3.2 (a measure of inflammation).
- You cannot have taken any biologic medicines (like Humira, Enbrel, or Actemra) or JAK inhibitors (like Xeljanz) in the past.
- You must be willing to complete a daily pain diary for at least 7 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.